Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Sallmon, H; Gutti, RK; Ferrer-Marin, F; Liu, ZJ; Sola-Visner, MC.
Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
J Perinatol. 2010; 30(12):765-9
Doi: 10.1038/jp.2010.50
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Sallmon Hannes
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The Food and Drug Administration recently approved two novel thrombopoiesis-stimulating agents, Romiplostim (AMG-531, Nplate) and Eltrombopag (Promacta), for the treatment of adults with immune thrombocytopenic purpura. For physicians taking care of critically ill neonates, this offers the opportunity of decreasing platelet transfusions and potentially improving the outcomes of neonates with severe and prolonged thrombocytopenia. However, several developmental factors need to be taken into consideration. First, the population of thrombocytopenic neonates likely to benefit from these agents needs to be carefully selected. Second, the mechanisms underlying neonatal and adult thrombocytopenia differ from each other and are incompletely understood, and pre-clinical evidence suggests that the response of neonates to thrombopoietic factors might be different from that of adults. Finally, the potential non-hematopoietic effects of thrombopoietin have not been well established. Here, we will discuss these issues in detail, and will highlight the critical developmental differences between neonates and adults that need to be considered as we think about introducing these agents into neonatal care.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Age Factors - administration & dosage
- Apoptosis - drug effects
- Benzoates - adverse effects, therapeutic use
- Brain - drug effects
- Dose-Response Relationship, Drug - administration & dosage
- Drug Approval - administration & dosage
- Humans - administration & dosage
- Hydrazines - adverse effects, therapeutic use
- Infant, Newborn - administration & dosage
- Neurons - drug effects
- Patient Selection - administration & dosage
- Platelet Transfusion - administration & dosage
- Purpura, Thrombocytopenic, Idiopathic - blood, drug therapy
- Pyrazoles - adverse effects, therapeutic use
- Receptors, Fc - therapeutic use
- Receptors, Thrombopoietin - agonists
- Recombinant Fusion Proteins - adverse effects, therapeutic use
- Thrombocytopenia, Neonatal Alloimmune - blood, drug therapy
- Thrombopoiesis - drug effects
- Thrombopoietin - adverse effects, therapeutic use
- United States - administration & dosage
- United States Food and Drug Administration - administration & dosage
- Find related publications in this database (Keywords)
- thrombocytopenia
- neonate
- thrombopoietin
- thrombopoietic growth factors